Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover
-
ナレーター：
-
著者：
このコンテンツについて
Link to CME: Claim Credit - https://bit.ly/3OByCaE
In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:
- How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settings
- The role of antiseizure medications in DEE treatment management
- The nonpharmacological treatment options available to patients with DEEs
- The emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s disease
- Results from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequency
- The future of soticlestat as a treatment option for pediatric patients with DEEs
Presenters:
Jonathan J. Halford, MD
Professor
Director, Translational Research Unit
Department of Neurology
Medical University of South Carolina
Charleston, SC
Cecil Hahn, MD, MPH, FRCPC
Professor
Pediatric Epileptologist
University of Toronto
Toronto, Ontario, Canada
Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Link to full program:
https://bit.ly/45UUpQy